(Q36845544)

16 August 2017

1 reference

title

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of L-arginine on its metabolism (English)

1 reference

16 August 2017

David E L Wilcken

1

1 reference

16 August 2017

Ah Siew Sim

series ordinal

2

1 reference

16 August 2017

Jun Wang

series ordinal

3

1 reference

16 August 2017

Xing Li Wang

series ordinal

4

1 reference

16 August 2017

publication date

7 June 2007

1 reference

Molecular Genetics and Metabolism

16 August 2017

published in

1 reference

16 August 2017

volume

91

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

309-17; discussion 308

1 reference

Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Traditional and emerging cardiovascular risk factors in end-stage renal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

The transplanted liver graft is capable of clearing asymmetric dimethylarginine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Elevation of asymmetric dimethylarginine (ADMA) in patients developing hepatic failure after major hepatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

The clinical significance of asymmetric dimethylarginine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Does ADMA cause endothelial dysfunction?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Effect of Shear Stress on Asymmetric Dimethylarginine Release From Vascular Endothelial Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Measurement of asymmetric dimethylarginine in plasma: methodological considerations and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Prognostic significance of endothelial dysfunction in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

High plasma arginine concentrations in critically ill patients suffering from hepatic failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Presence of methylated arginine derivatives in orthotopic human liver transplantation: relevance for liver function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

L-arginine regulates asymmetric dimethylarginine metabolism by inhibiting dimethylarginine dimethylaminohydrolase activity in hepatic (HepG2) cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Established and emerging plasma biomarkers in the prediction of first atherothrombotic events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

The natural history of vascular disease in homocystinuria and the effects of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: a multicenter observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Insulin resistance and protein catabolism in non-diabetic hemodialysis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in de

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Coronary stenosis dilatation induced by L-arginine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Vascular effects of dietary L-arginine supplementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Effects of oral L-arginine on endothelium-dependent vasodilation and markers of inflammation in healthy postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Oral L-arginine in patients with coronary artery disease on medical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Biochemical responses of healthy subjects during dietary supplementation with L-arginine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

What we know and don't know about L-arginine and NO

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Adverse effects of supplemental L-arginine in atherosclerosis: consequences of methylation stress in a complex catabolism?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2007.04.017

10.1016/J.YMGME.2007.04.017

7 January 2021

Identifiers

DOI

1 reference

release_4yke5viuercinimyuhxyllxsui

16 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4yke5viuercinimyuhxyllxsui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference